HF Advisory Group LLC Buys 146,444 Shares of IQVIA Holdings Inc. $IQV

Key Points

• HF Advisory Group LLC increased its IQVIA stake by 1,791.6% in Q4, purchasing 146,444 shares to hold 154,618 shares worth about $34.85 million, representing roughly 1.3% of the fund's portfolio and 0.09% of IQVIA.
• Analysts maintain a consensus "Buy" on IQVIA with a consensus price target of $229.13, amid mixed recent notes including Citigroup cutting its target to $200 (neutral) and TD Cowen upgrading to buy with a $213 target.
• IQVIA beat Q results with $3.42 EPS and $4.36B revenue, set FY2026 guidance of about 12.55–12.85 EPS, and currently trades near $172.66 with a market cap of ~$29.3 billion and a PE around 22.

HF Advisory Group LLC boosted its holdings in shares of IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 1,791.6% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 154,618 shares of the medical research company's stock after purchasing an additional 146,444 shares during the period. IQVIA comprises approximately 1.3% of HF Advisory Group LLC's investment portfolio, making the stock its 11th biggest position. HF Advisory Group LLC owned 0.09% of IQVIA worth $34,852,000 at the end of the most recent quarter.

Other institutional investors also recently modified their holdings of the company. Brighton Jones LLC raised its stake in IQVIA by 244.4% during the fourth quarter. Brighton Jones LLC now owns 3,575 shares of the medical research company's stock worth $703,000 after acquiring an additional 2,537 shares in the last quarter. Empowered Funds LLC lifted its holdings in shares of IQVIA by 102.1% in the first quarter. Empowered Funds LLC now owns 9,728 shares of the medical research company's stock worth $1,715,000 after acquiring an additional 4,915 shares during the last quarter. Sivia Capital Partners LLC bought a new stake in shares of IQVIA during the 2nd quarter valued at approximately $514,000. Elevation Point Wealth Partners LLC acquired a new position in IQVIA during the 2nd quarter worth approximately $64,000. Finally, Mackenzie Financial Corp boosted its position in IQVIA by 4.5% in the second quarter. Mackenzie Financial Corp now owns 36,546 shares of the medical research company's stock valued at $5,759,000 after buying an additional 1,561 shares in the last quarter. Institutional investors and hedge funds own 89.62% of the company's stock.

Analysts Set New Price Targets

IQV has been the subject of a number of research reports. Citigroup dropped their price target on IQVIA from $230.00 to $200.00 and set a "neutral" rating for the company in a research note on Friday, February 6th. Morgan Stanley set a $240.00 target price on IQVIA in a report on Wednesday, February 11th. Royal Bank Of Canada assumed coverage on IQVIA in a research note on Tuesday, March 3rd. They set an "outperform" rating and a $221.00 price target on the stock. Evercore restated an "outperform" rating and set a $225.00 price target on shares of IQVIA in a report on Thursday, February 5th. Finally, TD Cowen upgraded shares of IQVIA from a "hold" rating to a "buy" rating and raised their price objective for the company from $174.00 to $213.00 in a report on Monday, March 9th. Two research analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and two have given a Hold rating to the company's stock. According to MarketBeat, IQVIA currently has a consensus rating of "Buy" and a consensus price target of $229.13.

IQVIA Stock Up 1.2%

Shares of IQV opened at $172.66 on Thursday. The stock's 50-day moving average price is $182.63 and its two-hundred day moving average price is $204.96. IQVIA Holdings Inc. has a 12 month low of $134.65 and a 12 month high of $247.04. The company has a market capitalization of $29.30 billion, a PE ratio of 21.97, a PEG ratio of 1.65 and a beta of 1.39. The company has a current ratio of 0.75, a quick ratio of 0.75 and a debt-to-equity ratio of 2.09.

IQVIA (NYSE:IQV - Get Free Report) last issued its quarterly earnings data on Thursday, February 5th. The medical research company reported $3.42 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $3.40 by $0.02. The company had revenue of $4.36 billion during the quarter, compared to the consensus estimate of $4.24 billion. IQVIA had a return on equity of 30.50% and a net margin of 8.34%.The firm's revenue was up 10.3% compared to the same quarter last year. During the same period last year, the company earned $3.12 earnings per share. IQVIA has set its FY 2026 guidance at 12.550-12.850 EPS. On average, analysts anticipate that IQVIA Holdings Inc. will post 10.84 EPS for the current year.

About IQVIA

IQVIA NYSE: IQV is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA's principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.

Want to see what other hedge funds are holding IQV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IQVIA Holdings Inc. (NYSE:IQV - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.